title: Immunosuppressive effect on T cell activation by interleukin- 16-cDNA-transfected human squamous cell line.
abstract: It is well known that it is difficult to induce an immunotolerance with allogeneic skin transplantation. We attempted to find the immunosuppressive protocol for prolonging skin allograft rejection by using interleukin-16 because IL-16 is considered one of the natural ligands to CD4 molecules. First we examined whether synergistic immunosuppressive effects of recombinant IL-16 plus anti-CD4 mAbs are induced in mixed lymphocyte reaction (MLR). Next we used IL-16-cDNA-transfected OSC-20 (human oral squamous cell carcinoma cell line) as an in vitro model of the epidermal keratinocyte equivalent and examined whether this transfectant could inhibit the activation of allogeneic T cells. Our data indicated that IL-16 clearly inhibited human MLR and that IL-16 increased synergistically the immunosuppressive effect of anti-CD4 mAb. We also used IL-16 transfectant and this produced more than 50 ng/ml of IL-16 in the supernatant by which human MLR was significantly inhibited. Furthermore, this transfectant also inhibited the activation of allogeneic lymphocytes stimulated directly with transfectant cells. These results indicated that the IL-16-producing allogeneic skin graft might have a local immunosuppressive action that would prolong graft survival.
authors.affiliation: Division of Plastic Surgery, Sapporo Medical University School of Medicine, Sapporo, 060-8543, Japan. tfujita@sapmed.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Fujita
authors.forename: Y
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: I
authors.initials: I
authors.lastname: Hirai
authors.forename: K
authors.initials: K
authors.lastname: Ezoe
authors.forename: T
authors.initials: T
authors.lastname: Saito
authors.forename: A
authors.initials: A
authors.lastname: Yagihashi
authors.forename: T
authors.initials: T
authors.lastname: Torigoe
authors.forename: K
authors.initials: K
authors.lastname: Homma
authors.forename: S
authors.initials: S
authors.lastname: Takahashi
authors.forename: W W
authors.initials: WW
authors.lastname: Cruikshank
authors.forename: K
authors.initials: K
authors.lastname: Jimbow
authors.forename: N
authors.initials: N
authors.lastname: Sato
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015704:CD4 Antigens / Q000276:immunology*; D002460:Cell Line; D018076:DNA, Complementary; D004357:Drug Synergism; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D019410:Interleukin-16 / Q000235:genetics / Q000494:pharmacology*; D015603:Keratinocytes / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D007959:Lymphocyte Culture Test, Mixed; D011994:Recombinant Proteins / Q000494:pharmacology; D016038:Skin Transplantation / Q000276:immunology; D014162:Transfection; D014184:Transplantation, Homologous
chemical_list: D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D018076:DNA, Complementary; D007166:Immunosuppressive Agents; D019410:Interleukin-16; D011994:Recombinant Proteins